U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18N4O2
Molecular Weight 334.3718
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-1080

SMILES

OC1=C(C2=C(N1)C=CC(=C2)C#N)C3=NC=C(CN4CCOCC4)C=C3

InChI

InChIKey=BLTVBQXJFVRPFK-UHFFFAOYSA-N
InChI=1S/C19H18N4O2/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23/h1-4,9,11,22,24H,5-8,12H2

HIDE SMILES / InChI
AZ-1080 (AZD-1080) is an inhibitor of GSK-beta which was developed by AstraZeneca and initially tested in patients with Alzheimer’s disease (phase I). The drug was discontinued for the aforementioned condition, but now it is being investigated as a potential therapy for ovarina cancer and emdometrial carcinoma (basic research).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
31.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
86 nM
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AZD-1080 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
15 mg 1 times / day steady-state, oral
dose: 15 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AZD-1080 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day steady-state, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 15 mg, 1 times / day
Sources: Page: p.453
healthy, ADULT
n = 6
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources: Page: p.453
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.
2013 Oct
Patents

Sample Use Guides

Middle-aged subjects (45–64 years) receive 15 mg AZ-1080 once daily for 14 days.
Route of Administration: Oral
3T3 fibroblasts stably expressing human tau protein were treated with 1 uM of AZ-1080. Dose-dependent inhibition of tau phosphorylation was observed for AZ-1080 with IC50 value of 324 nM.
Name Type Language
AZD-1080
Code English
1H-INDOLE-5-CARBONITRILE, 2-HYDROXY-3-(5-(4-MORPHOLINYLMETHYL)-2-PYRIDINYL)-
Systematic Name English
AZ-11548415
Code English
2-HYDROXY-3-(5-((MORPHOLIN-4-YL)METHYL)PYRIDIN-2-YL)-1H-INDOLE-5-CARBONITRILE
Systematic Name English
Code System Code Type Description
ChEMBL
CHEMBL1969664
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY
PUBCHEM
135564570
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY
CAS
612487-72-6
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY
FDA UNII
0TII45R8IJ
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY
CHEBI
167651
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID70678598
Created by admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
PRIMARY